Have a feature idea you'd love to see implemented? Let us know!

ATRC AtriCure Inc

Price (delayed)

$35.68

Market cap

$1.74B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$1.69B

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure ...

Highlights
ATRC's revenue is up by 18% year-on-year and by 4.1% since the previous quarter
The company's gross profit rose by 17% YoY and by 4% QoQ
ATRC's net income has shrunk by 57% YoY but it is up by 3% QoQ
AtriCure's EPS has plunged by 54% YoY but it has increased by 3.5% from the previous quarter
The debt has grown by 3.7% YoY and by 2.4% from the previous quarter

Key stats

What are the main financial stats of ATRC
Market
Shares outstanding
48.75M
Market cap
$1.74B
Enterprise value
$1.69B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.74
Price to sales (P/S)
3.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.77
Earnings
Revenue
$447.57M
EBIT
-$31.03M
EBITDA
-$12.95M
Free cash flow
-$1.13M
Per share
EPS
-$0.83
Free cash flow per share
-$0.02
Book value per share
$9.55
Revenue per share
$9.5
TBVPS
$6.83
Balance sheet
Total assets
$615.07M
Total liabilities
$150.05M
Debt
$77.13M
Equity
$465.02M
Working capital
$194.86M
Liquidity
Debt to equity
0.17
Current ratio
3.62
Quick ratio
2.49
Net debt/EBITDA
4.11
Margins
EBITDA margin
-2.9%
Gross margin
74.8%
Net margin
-8.7%
Operating margin
-7.6%
Efficiency
Return on assets
-6.4%
Return on equity
-8.4%
Return on invested capital
-14.1%
Return on capital employed
-5.7%
Return on sales
-6.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATRC stock price

How has the AtriCure stock price performed over time
Intraday
-0.97%
1 week
1.05%
1 month
25.02%
1 year
-14.44%
YTD
-0.03%
QTD
27.25%

Financial performance

How have AtriCure's revenue and profit performed over time
Revenue
$447.57M
Gross profit
$334.72M
Operating income
-$34.16M
Net income
-$38.92M
Gross margin
74.8%
Net margin
-8.7%
ATRC's net income has shrunk by 57% YoY but it is up by 3% QoQ
The operating income has plunged by 54% YoY
The net margin has contracted by 34% YoY but it has grown by 6% from the previous quarter
The operating margin has declined by 31% year-on-year but it has grown by 6% since the previous quarter

Growth

What is AtriCure's growth rate over time

Valuation

What is AtriCure stock price valuation
P/E
N/A
P/B
3.74
P/S
3.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.77
AtriCure's EPS has plunged by 54% YoY but it has increased by 3.5% from the previous quarter
ATRC's price to book (P/B) is 26% lower than its 5-year quarterly average of 5.1 but 26% higher than its last 4 quarters average of 3.0
ATRC's P/S is 49% below its 5-year quarterly average of 7.5 but 15% above its last 4 quarters average of 3.3
ATRC's revenue is up by 18% year-on-year and by 4.1% since the previous quarter

Efficiency

How efficient is AtriCure business performance
The company's return on invested capital has shrunk by 88% YoY but it rose by 2.8% QoQ
The ROE has plunged by 56% YoY but it has grown by 3.4% from the previous quarter
AtriCure's return on assets has shrunk by 52% YoY but it has increased by 4.5% QoQ
AtriCure's ROS has decreased by 47% YoY but it has increased by 8% from the previous quarter

Dividends

What is ATRC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATRC.

Financial health

How did AtriCure financials performed over time
The current ratio is up by 18% year-on-year but it has declined by 12% since the previous quarter
AtriCure's quick ratio has increased by 11% YoY but it has decreased by 10% QoQ
The debt is 83% less than the equity
The debt to equity has grown by 6% since the previous quarter and by 6% year-on-year
The debt has grown by 3.7% YoY and by 2.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.